article · Scientific Reports
The RTS,S/AS01 malaria vaccine incorporates the circumsporozoite protein (PfCSP) based on the 3D7 parasite reference strain. Although earlier phase II trials did not detect strain-specific immunity, newer evidence indicates reduced vaccine efficacy against non-vaccine strains. To evaluate potential genetic mismatch, researchers deep-sequenced C-terminal Pfcsp from 77 individuals living along the border between Zambia and the Democratic Republic of the Congo. Among 193 parasite sequences analysed from this border area, only 5.2 per cent fully matched the 3D7 strain across all 84 amino acids. Comparison with 3,809 global Pfcsp sequences from 15 African and Asian countries demonstrated that this high level of diversity is mirrored globally. These findings highlight the need for further research into parasite genetic diversity to understand how sequence variation affects real-world vaccine protection during large-scale introduction.
Anticipating vaccine performance is critical for public health authorities planning widespread malaria immunisation programmes. Because the RTS,S/AS01 vaccine is derived from a single parasite strain, widespread genetic mismatch in local parasite populations could lower protection against disease. Documenting this diversity helps researchers and global health planners understand whether the vaccine will deliver its expected benefits across diverse regions.
This early-stage research provides genomic insights for vaccine developers, global health bodies, and national immunisation planners. While the abstract indicates no direct commercial product or pathway, the findings could guide the future design of multi-strain vaccines or inform regional deployment strategies. Translating this evidence into tailored vaccines or updated intervention policies represents an early-stage research and development effort.
AI-generated from the published abstract. Always read the original work before citing.
The RTS,S/AS01 malaria vaccine encompasses the central repeats and C-terminal of Plasmodium falciparum circumsporozoite protein (PfCSP). Although no Phase II clinical trial studies observed evidence of strain-specific immunity, recent studies show a decrease in vaccine efficacy against non-vaccine strain parasites. In light of goals to reduce malaria morbidity, anticipating the effectiveness of RTS,S/AS01 is critical to planning widespread vaccine introduction. We deep sequenced C-terminal Pfcsp from 77 individuals living along the international border in Luapula Province, Zambia and Haut-Katanga Province, the Democratic Republic of the Congo (DRC) and compared translated amino acid haplotypes to the 3D7 vaccine strain. Only 5.2% of the 193 PfCSP sequences from the Zambia-DRC border region matched 3D7 at all 84 amino acids. To further contextualize the genetic diversity sampled in this study with global PfCSP diversity, we analyzed an additional 3,809 Pfcsp sequences from the Pf3k database and constructed a haplotype network representing 15 countries from Africa and Asia. The diversity observed in our samples was similar to the diversity observed in the global haplotype network. These observations underscore the need for additional research assessing genetic diversity in P. falciparum and the impact of PfCSP diversity on RTS,S/AS01 efficacy.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1038/s41598-018-24585-8
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
